Albireo Pharma, Inc. is a startup based in the United States, most recent round Series-c-plus.
Based in the United States, Albireo Pharma, Inc. is a startup. Its most recent tracked round is Series-c-plus.
Albireo Pharma, Inc. is a biopharmaceutical company developing therapies for rare pediatric and adult cholestatic liver diseases; its lead product, odevixibat (Bylvay), is an oral ileal bile acid transporter inhibitor approved for certain rare cholestatic liver conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.